Rigel receives EMA Validation of the MAA for fostamatinib disodium hexahydrate in ITP
Rigel Pharmaceuticals announced the EMA has validated the MAA for fostamatinib in adult chronic immune thrombocytopenia. The validation was received Oct. 4, 2018 and initiated the MAA review process. The company anticipates a decision from the CHMP by the fourth quarter of 2019. October 11, 2018
